Public Health Service, NIH & CDC

The Public Health Service (PHS) — the federal public health infrastructure established by the Public Health Service Act of 1944 (42 U.S.C. Chapter 6A) — is the umbrella framework for a network of agencies within the Department of Health and Human Services that conduct medical research, track disease, train the health workforce, and respond to public health emergencies. The crown jewel is the National Institutes of Health (NIH) — funded at approximately $48 billion/year, making it the world's largest public biomedical research funder, supporting over 300,000 researchers at more than 2,500 universities and research institutions through competitive grants. NIH-funded research has contributed to virtually every major medical advance of the past 50 years, including the mRNA vaccine technology that enabled COVID-19 vaccines (developed at NIH with Moderna). The Centers for Disease Control and Prevention (CDC) — funded at approximately $9 billion/year — monitors disease trends, runs vaccination programs, responds to outbreaks, and publishes the epidemiological data that guides public health policy. The COVID-19 pandemic revealed both the strengths and limitations of the PHS structure: NIH's research engine produced vaccines in record time, while CDC's communication and response faced significant credibility challenges. The Trump administration's 2025 restructuring of HHS — including a proposed NIH consolidation from 27 institutes and centers to 15, and DOGE-driven staff cuts at CDC — has created significant uncertainty about the agencies' capacity to conduct ongoing research and maintain public health surveillance functions.

Current Law (2026)

Legal Authority

• 42 U.S.C. § 201-202 — Public Health Service organization (PHS within HHS; Surgeon General as chief health officer; PHS Commissioned Corps as one of the eight uniformed services)
• 42 U.S.C. § 204 — Commissioned Corps and Ready Reserve Corps (officers serve in public health emergencies, disease outbreaks, and disaster response; ranks parallel military structure)
• 42 U.S.C. § 241 — Research and investigations (Surgeon General authorized to conduct and support research, investigations, experiments, and demonstrations relating to the causes, diagnosis, treatment, control, and prevention of diseases and conditions)
• 42 U.S.C. § 243 — General grant of authority for cooperation (Secretary may cooperate with states, political subdivisions, and other organizations in the prevention and suppression of communicable diseases; grants and technical assistance)
• 42 U.S.C. § 247b — Preventive health services (project grants to states and other entities for communicable disease control, chronic disease prevention, immunization, and other preventive services — the core CDC grant authority)
• 42 U.S.C. § 247d — Public health emergencies (Secretary may determine that a public health emergency exists and take emergency response actions; Public Health Emergency Fund; Strategic National Stockpile; emergency use authorizations)
• 42 U.S.C. § 254b — Community Health Centers (grants to public and nonprofit organizations to operate health centers providing primary care to medically underserved populations; Federally Qualified Health Centers — FQHCs — serve all patients regardless of ability to pay)
• 42 U.S.C. § 254e — Health Professional Shortage Areas (Secretary designates HPSAs based on population-to-provider ratios; NHSC loan repayment and scholarship programs to incentivize service in underserved areas)
• 42 U.S.C. § 282 — Director of NIH (oversees all NIH institutes and centers; coordinates biomedical research strategy; sets priorities across the research portfolio)
• 42 U.S.C. § 284 — Directors of national research institutes (each of the 27 institutes has a director who plans and conducts research programs in the institute's designated area)
• 42 U.S.C. § 290aa — SAMHSA (Substance Abuse and Mental Health Services Administration — leads federal efforts to reduce the impact of substance abuse and mental illness; block grants to states; treatment and prevention programs; 988 Suicide and Crisis Lifeline)

How It Works

The Public Health Service Act provides the legal foundation for the federal government's public health infrastructure — from cutting-edge biomedical research at NIH to frontline disease prevention at CDC to community-based healthcare delivery through Federally Qualified Health Centers.

The National Institutes of Health (NIH) is the world's largest public funder of biomedical research, with a budget of approximately $48 billion spread across 27 institutes and centers including the National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Allergy and Infectious Diseases (NIAID), and National Institute of Mental Health (NIMH). About 80% of NIH's budget flows to approximately 2,500 universities, medical schools, and research institutions through competitive grants; intramural research at NIH's campus accounts for about 10%. NIH research has produced foundational advances including the Human Genome Project, mRNA vaccine technology, HIV/AIDS treatments, and cancer immunotherapy. The Centers for Disease Control and Prevention (CDC) is the nation's public health protection agency — monitoring disease outbreaks, investigating epidemics, conducting surveillance, operating laboratory networks, providing immunization guidance through the Advisory Committee on Immunization Practices (ACIP), and coordinating emergency public health response. CDC works primarily through state and local health departments, providing approximately $9 billion per year in funding, technical assistance, and laboratory support; the National Notifiable Diseases Surveillance System and BioSense Platform provide the nation's early warning system for health threats.

The PHS Act's Section 330 funds approximately 1,400 Federally Qualified Health Centers (FQHCs) operating 15,000 sites and serving 31 million patients — about 1 in 11 Americans. FQHCs provide comprehensive primary care (medical, dental, behavioral health, pharmacy) regardless of ability to pay, using sliding fee scales based on income. They receive enhanced Medicaid/Medicare reimbursement rates, medical malpractice coverage through the Federal Tort Claims Act, and eligibility for the 340B Drug Pricing Program; they must serve medically underserved populations and be governed by community boards with patient majorities. SAMHSA (the Substance Abuse and Mental Health Services Administration) leads federal behavioral health efforts — administering the Substance Abuse Prevention and Treatment Block Grant and Community Mental Health Services Block Grant to states, funding the 988 Suicide and Crisis Lifeline, and overseeing treatment access. Section 247d gives the HHS Secretary authority to declare public health emergencies, unlocking emergency funding, waiving regulatory requirements, and activating the Strategic National Stockpile of medical countermeasures — authority used extensively during COVID-19, Ebola outbreaks, and natural disasters.

How It Affects You

State Variations

Implementing Regulations

• 42 CFR Part 52 — Grants for health services research and development (NIH research grants, project grants, cooperative agreements)

• 42 CFR Part 68 — National Health Service Corps (NHSC) scholarship and loan repayment programs

• 42 CFR Part 70–71 — Interstate and foreign quarantine (CDC communicable disease control, isolation/quarantine authority, travel restrictions)

• 42 CFR Part 11 — Clinical Trials Registration and Results Information Submission (ClinicalTrials.gov): the HHS implementing regulation for section 402(j) of the PHS Act (42 U.S.C. § 282(j)), which requires sponsors and investigators conducting applicable clinical trials to register on ClinicalTrials.gov before enrollment begins and to report results after completion. This is among the most consequential transparency regulations in clinical research:

  • § 11.22 — Which trials must register: "applicable clinical trials" must register — this covers Phase 2, 3, and 4 controlled clinical investigations (not Phase 1) of FDA-regulated drugs, biologics, and devices that meet size or enrollment criteria; also covers pediatric postmarket surveillance studies; trials of dietary supplements, surgical techniques, and behavioral interventions that don't involve FDA-regulated products are not "applicable clinical trials" but may still voluntarily register
  • § 11.24 — Registration deadline: the responsible party must submit registration information to ClinicalTrials.gov no later than 21 days after enrollment of the first participant; for trials completed before the rule took effect (March 2017), there were grace period deadlines; late registration violates the regulation and can result in civil monetary penalties up to $10,000/day plus enforcement actions affecting NIH funding eligibility
  • § 11.28 — Registration information: mandatory registration fields include the trial's official title and brief description, condition or disease studied, intervention type and name, primary outcome measure (with time frame and description), secondary outcome measures, study design (allocation, masking, phase), eligibility criteria, primary completion date and estimated enrollment, responsible party contact, sponsor, collaborators, and study sites; the registration creates a public record that allows participants to find trials and investigators to identify concurrent or prior similar work
  • § 11.40–11.44 — Results reporting: for trials whose studied product is FDA-approved/cleared/licensed, results must be submitted within 1 year of the primary completion date; for trials of unapproved/unlicensed products, results must be submitted within 1 year unless a certification for delayed results is filed (permitted for up to 2 additional years while a marketing application is pending); required results fields include: participant flow (enrollment, completions, dropouts), baseline characteristics, primary and secondary outcome measure results (with statistical significance data), adverse events (serious and non-serious), and point-of-contact information
  • § 11.66 — Enforcement: failure to register or report results on time subjects the responsible party to civil monetary penalties; for NIH-funded studies, failure to comply can result in suspension or termination of grant funding; the FDA Reauthorization Act of 2017 (FDARA) reinforced enforcement by requiring NIH to notify responsible parties of violations and making persistent non-compliance grounds for grant termination

  The ClinicalTrials.gov registration requirement addresses the publication bias problem: historically, positive clinical trial results were published at much higher rates than negative results, distorting the medical literature's picture of treatment efficacy. Mandatory registration creates a complete record of all trials begun, not just those eventually published — allowing systematic reviewers, regulators, and physicians to know about unpublished negative results. Recent rulemakings: 81 FR 64981 (September 2016) — the final rule establishing the current Part 11 framework with results reporting requirements, effective January 18, 2017.

• 42 CFR Part 73 — Select Agents and Toxins (CDC HHS oversight): the regulatory framework implementing the Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (42 U.S.C. § 262a), requiring anyone who possesses, uses, or transfers listed dangerous biological agents and toxins to register with CDC and comply with stringent biosafety and security requirements. Key provisions:

  • §§ 73.3–73.4 — The Select Agent Lists: HHS select agents (§ 73.3) are biological agents CDC has determined pose a severe threat to public health and safety — currently including Ebola virus, Marburg virus, smallpox (Variola major), SARS-CoV, and toxins like botulinum toxin and ricin; Overlap select agents (§ 73.4) pose threats to both human and animal health and are jointly regulated by CDC/HHS and USDA/APHIS — including anthrax (Bacillus anthracis), foot-and-mouth disease virus, and avian influenza viruses; Tier 1 agents within the list represent the highest risk of significant potential for mass casualties or devastating effects on the economy and critical infrastructure — they face additional security requirements
  • §§ 73.5–73.6 — Exemptions: clinical and diagnostic laboratories that receive specimens containing select agents for diagnosis or verification are exempt if they: do not use or transfer the agent or toxin; destroy the specimen within 7 days unless they apply for a diagnostic exception; and report their possession to CDC within 90 days; this exemption is critical for public health — it allows hospitals and clinical labs to test patient specimens without full select agent registration
  • § 73.7 — Registration and security risk assessment: no individual or entity may possess, use, or transfer any HHS select agent without a CDC certificate of registration; before registration is approved, the Attorney General (FBI) must conduct a security risk assessment of each individual who will have access to the select agents; registration is denied to: individuals with criminal convictions for certain offenses; individuals deemed to be a security threat; entities under certain foreign ownership or control; registration must be renewed every 3 years
  • § 73.9 — Responsible Official (RO): each registered entity must designate a Responsible Official — an individual approved by CDC after an FBI security risk assessment — who has authority to ensure compliance with select agent regulations; the RO must be onsite (or immediately available) when select agent work is being conducted; the RO is personally accountable for program compliance
  • § 73.10 — Restricting access: a registered entity may not allow any individual to access select agents unless that individual has passed an FBI security risk assessment and been approved by CDC; workers with access must be specifically listed in the registration; access is controlled at two levels: (a) individual registration approval; and (b) physical access controls limiting presence in areas where select agents are stored or used
  • § 73.11 — Security plan: every registered entity must have a written security plan implementing FSAP (Federal Select Agent Program) guidelines appropriate to the risk posed by the agent; for Tier 1 agents, security requirements are more stringent — including physical security zones, intrusion detection, and on-site security personnel for the most dangerous materials
  • § 73.12 — Biosafety plan: a written biosafety plan commensurate with the risk and intended use is required; the plan must address containment, safety equipment, training, and emergency procedures specific to each agent; most CDC-regulated work requires at least BSL-3 (Biosafety Level 3) physical containment (directional airflow, sealed lab entry, respiratory protection); smallpox-related work requires BSL-4 containment
  • § 73.13 — Restricted experiments: certain experiments with select agents require advance HHS Secretary approval — including experiments that would significantly increase transmissibility or virulence, introduce resistance to therapies, or enhance the ability to evade immune responses; this is the primary regulation governing gain-of-function (GOF) research and the broader "potential pandemic pathogen enhancement" (ePPP) category of research; the dual-use research of concern (DURC) framework operates alongside these regulations
  • § 73.19 — Theft, loss, or release notification: any theft or loss of a select agent must be reported immediately to CDC and appropriate law enforcement; accidental releases must be reported to CDC within 24 hours; these notifications trigger federal law enforcement response and public health investigation

  Part 73 reflects the post-9/11 and post-anthrax-letters biosecurity framework — the anthrax letter attacks of 2001 demonstrated that biological agents could be weaponized and delivered through ordinary postal infrastructure. The registration system ensures that CDC and law enforcement know exactly who has each select agent, where it is stored, and under what conditions. The "gain-of-function" controversy that emerged prominently around COVID-19 origins focused on the § 73.13 restricted experiments process — the question of whether certain gain-of-function research at international facilities (including in Wuhan) should have required advance HHS approval remains contested. Recent rulemakings: 85 FR 43388 (July 2020) — added SARS-CoV-2 variants and related coronaviruses to the oversight framework; 88 FR 54402 (August 2023) — updated the select agent list removing some agents and adjusting Tier 1 designations.

• 42 CFR Part 50 — Policies of General Applicability (federal financial assistance for biomedical and health services research; protection of human subjects; financial conflicts of interest; research misconduct procedures; 36 sections)

• 42 CFR Part 93 — Public Health Service Policies on Research Misconduct (research misconduct definitions: fabrication, falsification, plagiarism; institutional and federal investigation procedures; administrative actions and findings; 100 sections)

• 42 CFR Part 21 — PHS Commissioned Corps — Officer Appointment and Eligibility: the regulatory framework governing how candidates are examined, appointed, and graded in the PHS Commissioned Corps, one of the eight uniformed services of the United States. PHS officers hold military-equivalent ranks (O-1 through O-9), receive military pay and benefits, and serve wherever the Surgeon General directs — at Indian Health Service clinics, FDA field offices, CDC laboratories, the Bureau of Prisons, FEMA disaster deployments, and international health missions. The Corps currently has approximately 6,000 active-duty commissioned officers across health professional categories (physicians, nurses, pharmacists, dentists, dietitians, environmental health officers, health service officers, mental health counselors, and others). Key provisions:

  • § 21.22 — Examination applications: every officer candidate must submit a formal written application; the Surgeon General sets the application form and examination process; false statements are grounds for rejection or dismissal (§ 21.23)
  • § 21.24 — Physical examination: all candidates must pass a physical exam meeting Surgeon General-set standards; physical fitness standards differ somewhat from military services given the public health rather than combat mission
  • § 21.25 — Junior assistant grade (O-1/O-2 equivalent): entry-level grade; requires a qualifying health professional degree and a valid license; specific degree and licensure requirements vary by professional category (a physician must hold an M.D. or D.O. and a state license; a pharmacist must hold a Pharm.D. or B.S. Pharm. and state license)
  • § 21.26–21.27 — Assistant and senior assistant grades (O-3/O-4): progressively higher grades require additional years of creditable professional experience; the number of qualifying years is weighted by degree level and postgraduate training (e.g., residency years count differently than practice years)
  • § 21.28 — Age requirements: no candidate may be appointed to the Regular Corps (permanent commissioned status) after age 31 for grades of senior assistant and below, except nurses (who have a higher age ceiling); this age limit reflects the career-length investment the Corps makes in each officer and is analogous to commissioning age limits in the military services; there are exceptions for direct appointments at higher grades (§ 21.29)
  • § 21.29 — Grades above senior assistant (O-5 and above): appointments at the full commander / director grade and above require additional experience beyond what lower-grade exams establish; the Surgeon General may set specific requirements by professional category
  • § 21.30–21.31 — Creditable experience determination: the Surgeon General is authorized to establish detailed rules for counting educational and professional experience toward grade placement; quality as well as quantity of training counts; post-doctoral fellowships, residency programs, and advanced specialty training receive additional credit

  Part 21 reflects the Corps' role as a uniformed professional health force rather than a traditional military branch. The examination-and-grade structure parallels military officer commissioning but calibrates grade to professional education and experience rather than a standardized officer training course. Importantly, PHS Commissioned Corps officers can be detailed to any federal department or agency — IHS, EPA, FDA, FEMA, Coast Guard, State Department — giving the Surgeon General a flexible public health workforce that can surge to meet national emergencies. This interagency deployment authority distinguishes the Corps from civil service employees, who are generally agency-specific.

• 42 CFR Part 66 — National Research Service Awards (23 sections across two subparts): the PHS regulations implementing the National Research Service Award (NRSA) program under PHS Act § 487 (42 U.S.C. § 288), which provides fellowship and training support for biomedical and behavioral research — one of the federal government's primary mechanisms for training the next generation of biomedical scientists. NRSAs fund both individual fellowships (Subpart A — F-series NIH awards: F30, F31, F32, F99/K00) and institutional training grants (Subpart B — T-series awards: T32, T35). Key provisions:

  • § 66.103 — Eligibility: to receive a direct NRSA, an individual must be (a) a U.S. citizen, noncitizen national, or lawful permanent resident; (b) proposing to engage in full-time research training — exceptions only for disability or pressing family need; (c) at the appropriate career stage for the fellowship type (predoctoral, postdoctoral, or established researcher); non-citizen international scholars may not receive individual NRSAs (a significant limitation that directs NIH training funds to domestic talent development)
  • § 66.104 — Application: applications for individual fellowships are submitted by the prospective fellow through their sponsoring institution; the sponsoring institution certifies the adequacy of the training environment and the availability of the supervising mentor; the institutional role distinguishes NRSAs from independent research grants — the training relationship between mentor and fellow is integral to the award
  • § 66.105 — Award terms: NRSA stipend levels are set annually by NIH based on career level — in 2024, predoctoral stipends start at approximately $28,000/year; postdoctoral stipends range from $61,000 to $72,000 based on years of experience; in addition to the stipend, NRSAs include an allowance for tuition/fees, institutional allowance for training costs, and travel support
  • § 66.107 — Service payback requirement: individuals who receive more than 12 months of NRSA postdoctoral support are subject to a service payback obligation — they must engage in health-related biomedical or behavioral research, research training, or health-related teaching for a period equal to the excess months of support; this requirement ensures federal training investment is repaid through contribution to the scientific workforce; payback may be fulfilled through employment in academic, government, nonprofit, or industry research settings
  • § 66.108 — Repayment of stipend: fellows who fail to fulfill the service payback obligation must repay the amount received for excess months of NRSA support; HHS may collect unpaid repayment obligations through administrative offset against other federal payments
  • Subpart B — Institutional Training Grants (§§ 66.201–66.210): T32 and T35 grants are awarded to institutions (universities and research centers) rather than individuals; the institution recruits and selects trainees using federal funds; institutional grants allow NIH to build training capacity in specific research areas (e.g., a T32 for genomic medicine, a T35 for summer undergraduate research); trainees funded through institutional grants have the same citizenship eligibility requirements and service payback obligations as individual fellows

  The NRSA program is the primary vehicle by which NIH trains Ph.D. scientists, M.D.-Ph.D. investigators, and postdoctoral researchers for careers in biomedical research. NIH spent approximately $2.1 billion on NRSA and related training grants in FY 2024. The F31 fellowship is the standard predoctoral award for Ph.D. students in biomedical sciences; the F32 is the standard postdoctoral fellowship; the K99/R00 is a pathway-to-independence award bridging postdoctoral training to an independent faculty position. Recent rulemaking: 89 FR 80068 (October 2024) — updated stipend levels and clarified payback calculation procedures.

Pending Legislation

• HR 6867 — NIH Clinical Trial Integrity Act: requires demographic enrollment goals and outreach to diversify clinical research. Status: Introduced.
• S 3254 — NIH IMPROVE Act: funds research to cut maternal deaths and narrow racial disparities. Status: Introduced.
• HR 6782 — Public Health Air Quality Act of 2025: nationwide air monitoring for fencelines and communities. Status: Introduced.
• HR 2439 — Resident Physician Shortage Reduction Act of 2025: would create ~2,000 new Medicare-funded residency slots per year from 2027-2033, prioritizing rural and underserved hospitals. Status: Introduced.
• HR 2371 — Safe Baby Formula Act of 2025: would require HHS to study toxic metals in baby formula and set enforceable contamination limits. Status: Introduced.
• HR 2341 — Ensuring Safe and Toxic-Free Foods Act of 2025: new GRAS framework with public notice/comment and recurring reassessment program for food chemicals. Status: Introduced.
• HR 2353 — Microplastics Safety Act: would direct HHS to study how microplastics in food and water affect health and report to Congress within one year. Status: Introduced.
• HR 2340 — Climate Change Health Protection and Promotion Act of 2025: would create an HHS Office to prepare health systems for climate impacts. Status: Introduced.
• HR 2131 — Dads Matter Act of 2025: requires HHS nationwide campaign and state guidance to boost father engagement during pregnancy, birth, and postpartum. Status: Introduced.

Recent Developments

• Post-COVID restructuring of public health emergency preparedness — increased emphasis on pandemic readiness, supply chain resilience, and rapid medical countermeasure development
• ARPA-H (established 2022) is ramping up operations with a focus on breakthrough health technologies
• Community Health Center funding remains subject to periodic reauthorization, creating uncertainty for the 31 million patients served
• The 988 Suicide and Crisis Lifeline (launched 2022) has handled millions of calls, texts, and chats, transforming crisis intervention access
• NIH has faced political scrutiny over research funding decisions, gain-of-function research policies, and transparency
• In February 2026, the House Energy and Commerce Committee marked up 13 health-related bills including the SHINE for Autumn Act (stillbirth prevention), the Autism Collaboration, Accountability, and Transparency Act (H.R. 7213), and other public health measures — reflecting continued bipartisan legislative activity on targeted health policy improvements.